1. |
Zhao L, Pang P, Zang L, et al. Features and trends of thyroid cancer in patients with thyroidectomies in Beijing, China between 1994 and 2015: a retrospective study. BMJ Open, 2019, 9(1): e023334.
|
2. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021 Feb 4. doi: 10.3322/caac.21660. Online ahead of print.
|
3. |
Zhang J, Cheng X, Shen L, et al. The association between lymph node stage and clinical prognosis in thyroid cancer. Front Endocrinol (Lausanne), 2020, 11: 90.
|
4. |
黄璐, 李超, 王薇, 等. 甲状腺癌腺外侵犯的意义及最新研究进展. 中华耳鼻咽喉头颈外科杂志, 2019, 54(9): 717-720.
|
5. |
中华人民共和国国家卫生健康委员会. 甲状腺癌诊疗规范(2018年版). 中华普通外科学文献(电子版), 2019, 13(1): 1-15.
|
6. |
Kim KJ, Kim SG, Tan J, et al. BRAFV600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma. Eur J Cancer, 2020, 124: 161-169.
|
7. |
Huang Y, Qu S, Zhu G, et al. BRAFV600E mutation-assisted risk stratification of solitary intrathyroidal papillary thyroid cancer for precision treatment. J Natl Cancer Inst, 2018, 110(4): 362-370.
|
8. |
Cabanillas ME, Ryder M, Jimenez C. Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr Rev, 2019, 40(6): 1573-1604.
|
9. |
McLeod DSA, Zhang L, Durante C, et al. Contemporary debates in adult papillary thyroid cancer management. Endocr Rev, 2019, 40(6): 1481-1499.
|
10. |
宋创业, 严丽, 孟艳林, 等. BRAFV600E突变在cN0期PTMC颈中央区淋巴结转移中的预测价值. 中华普外科手术学杂志(电子版), 2020, 14(6): 631-634.
|
11. |
Gouveia C, Can NT, Bostrom A, et al. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. JAMA Otolaryngol Head Neck Surg, 2013, 139(11): 1164-1170.
|
12. |
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid, 2016, 26(1): 1-133.
|
13. |
Amin MB, Edge S, Greene F, et al. AJCC Cancer Staging Manual. 8th edn. New York, NY: Springer International Publishing, 2017.
|
14. |
Sugino K, Nagahama M, Kitagawa W, et al. Risk stratification of pediatric patients with differentiated thyroid cancer: is total thyroidectomy necessary for patients at any risk? Thyroid, 2020, 30(4): 548-556.
|
15. |
宋韫韬, 于文斌, 魏炜, 等. 甲状腺乳头状癌腺外侵犯相关因素分析. 中国实用外科杂志, 2017, 37(11): 1272-1275.
|
16. |
Li G, Li R, Song L, et al. Implications of extrathyroidal extension invading only the strap muscles in papillary thyroid carcinomas. Thyroid, 2020, 30(1): 57-64.
|
17. |
崔文霞, 朱有志, 郑珂, 等. 甲状腺乳头状癌BRAFV600E基因突变与蛋白表达的临床研究. 中华实验外科杂志, 2018, 35(3): 522-524.
|
18. |
Lim JY, Hong SW, Lee YS, et al. Clinicopathologic implications of the BRAFV600E mutation in papillary thyroid cancer: a subgroup analysis of 3 130 cases in a single center. Thyroid, 2013, 23(11): 1423-1430.
|
19. |
Yan C, Huang M, Li X, et al. Relationship between BRAFV600E and clinical features in papillary thyroid carcinoma. Endocr Connect, 2019, 8(7): 988-996.
|
20. |
王越, 赵文娟. 桥本氏甲状腺炎合并PTC临床病理特征与BRAFV600E基因突变的相关性研究, 青岛大学, 2019.
|
21. |
Kim WW, Ha TK, Bae SK. Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis. J Otolaryngol Head Neck Surg, 2018, 47(1): 4.
|
22. |
Kim SK, Woo JW, Lee JH, et al. Chronic lymphocytic thyroiditis and BRAFV600E in papillary thyroid carcinoma. Endocr Relat Cancer, 2016, 23(1): 27-34.
|
23. |
Molnár C, Molnár S, Bedekovics J, et al. Thyroid carcinoma coexisting with Hashimoto’s thyreoiditis: clinicopathological and molecular characteristics clue up pathogenesis. Pathol Oncol Res, 2019, 25(3): 1191-1197.
|
24. |
Pessôa-Pereira D, Medeiros MFDS, Lima VMS, et al. Association between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series. Arch Endocrinol Metab, 2019, 63(2): 97-106.
|
25. |
Biondi B, Cappola AR, Cooper DS. Subclinical hypothyroidism: A review. JAMA, 2019, 322(2): 153-160.
|
26. |
Vita R, Ieni A, Tuccari G, et al. The increasing prevalence of chronic lymphocytic thyroiditis in papillary microcarcinoma. Rev Endocr Metab Disord, 2018, 19(4): 301-309.
|
27. |
Marotta V, Sciammarella C, Chiofalo MG, et al. Hashimoto’s thyroiditis predicts outcome in intrathyroidal papillary thyroid cancer. Endocr Relat Cancer, 2017, 24(9): 485-493.
|
28. |
张艳, 王文栋, 兰霞斌, 等. 甲状腺乳头状癌伴发桥本甲状腺炎的临床研究. 中国癌症杂志, 2019, 29(12): 948-954.
|
29. |
税春燕, 李超, 覃纲, 等. 甲状腺乳头状癌临床病理特征对颈部淋巴结转移风险预测. 中华肿瘤防治杂志, 2019, 26(13): 952-958.
|
30. |
Jain NK, Mostoufi-Moab S, Hawkes CP, et al. Extrathyroidal extension is an important predictor of regional lymph node metastasis in pediatric differentiated thyroid cancer. Thyroid, 2020, 30(7): 1037-1043.
|
31. |
Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab, 2001, 86(4): 1447-1463.
|
32. |
Sulaieva O, Chernenko O, Chereshneva Y, et al. Thyroid stimulating hormone levels and BRAFV600E mutation contribute to pathophysiology of papillary thyroid carcinoma: Relation to outcomes? Pathophysiology, 2019, 26(2): 129-135.
|